Abivax SA (ABVX PA) stock market data APIs
€119.3425
-3.03(-2.5%)
as of July 17, 2026
Try our APIs with
free plan!
Abivax SA Financial Data Overview
Price chart is built with
Anychart
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
119.3425
Open
116.3142
High
121.7047
Low
115.9134
52 wk Range
8.58-139
Market Cap
10 390 M
Shares Outstanding
87 161 K
Revenue
4 920 K
EPS
-0.61
Beta
-0.211
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abivax SA (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abivax SA data using free add-ons & libraries
Get Abivax SA Fundamental Data
Abivax SA Fundamental data includes:
- Net Revenue: 4 920 K
- EBITDA: -254 004 000
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-22
- EPS/Forecast: -0.85
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abivax SA News
New
3 Soaring Stocks That May Have More Upside Ahead
"Buy low" is a common investing phrase that some people may interpret as "buy after a pullback." However, even near all-time highs, a stock can be at a "low" point, provided there are good reasons to ...
Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says
Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Jefferies upgrades Abivax to Buy, lifts PT as safety concerns over obefazimod ease
Investing.com -- Jefferies upgraded Abivax to "Buy" from "Hold" and raised its price target to $158 from $108 after updated Phase 3 data for its lead drug candidate, obefazimod, alleviated concerns ov...
Abivax (ABVX) Reports Q1 2026 Financial Results with Cash Runway Extending Through 2027
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best young stocks to invest in according to hedge funds. On May 22, Abivax reported Q1 2026 financial results, highlighting a solid cash position o...
Get Abivax SA fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
